Joseph G. Pressey · Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung
Follow
Article1 min read·Published Apr 2020Older

Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Apr 2020 · 1 min read

In brief

In brief

Phase 2.5 randomized, placebo-controlled trial evaluating saracatinib (AZD0530), an oral Src kinase inhibitor, in 37 patients following complete resection of osteosarcoma lung metastases. Despite good tolerability, saracatinib showed no significant improvement in progression-free survival compared to placebo.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Purpose: Osteosarcoma is a rare cancer and a third of patients who have completed primary treatment will develop osteosarcoma recurrence. The Src pathway has been implicated in the metastatic behavior of osteosarcoma; about 95% of samples examined express Src or have evidence of downstream activation of this pathway. Saracatinib (AZD0530) is a potent and selective Src kinase inhibitor that was evaluated in adults in Phase 1 studies. The primary goal of this study was to determine if treatment with saracatinib could increase progression-free survival (PFS) for patients who have undergone complete resection of osteosarcoma lung metastases in a double-blinded, placebo-controlled trial. Patients and Methods. Subjects with recurrent osteosarcoma localized to lung and who had complete surgical removal of all lung nodules were randomized within six weeks after complete surgical resection. Saracatinib, or placebo, was administered at a dose of 175 mg orally, once daily, for up to thirteen 28-day cycles. Results: Thirty-seven subjects were included in the analyses; 18 subjects were randomized to receive saracatinib and 19 to receive placebo. Intent-to-treat analysis demonstrated a median PFS of 19.4 months in the saracatinib treatment group and 8.6 months in the placebo treatment group (p=0.47). Median OS was not reached in either arm. Conclusions: Although saracatinib was well tolerated in this patient population, there was no apparent impact of the drug in this double-blinded, place

Statements in this article

  1. A third of osteosarcoma patients who have completed primary treatment will develop osteosarcoma recurrence.

    EstablishedPurpose
  2. About 95% of osteosarcoma samples examined express Src or have evidence of downstream activation of this pathway.

    ResearchPurpose
  3. Subjects with recurrent osteosarcoma localized to lung who had complete surgical removal of all lung nodules were randomized within six weeks after complete surgical resection.

    RecommendationPatients and Methods
  4. Saracatinib was administered at a dose of 175 mg orally, once daily, for up to thirteen 28-day cycles.

    RecommendationPatients and Methods
  5. Thirty-seven subjects were included in the analyses; 18 subjects were randomized to receive saracatinib and 19 to receive placebo.

    ResearchResults
  6. Intent-to-treat analysis demonstrated a median PFS of 19.4 months in the saracatinib treatment group and 8.6 months in the placebo treatment group (p=0.47).

    ResearchResults
  7. Median OS was not reached in either arm.

    ResearchResults
  8. Saracatinib was well tolerated in this patient population.

    ResearchConclusions
  9. There was no apparent impact of saracatinib in this double-blinded, placebo-controlled trial.

    ResearchConclusions

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.